Kardigan, Inc.
Limited financial coverage for KARD.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Range $37 – $40
Price Chart
About the company
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes.
- CEO
- Tassos Gianakakos
- IPO
- 2026
- Employees
- 241
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on KARD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- 52W High
- $27.00
- 52W Low
- $16.25
- 50D MA
- $22.87
- 200D MA
- $22.87
- Beta
- 0.00
- RSI (14)
- 43
- Avg Volume
- 702.88K
No earnings-call transcripts are available for KARD yet.
- Free Float
- 56.2%
- Shares Outstanding
- 89.34M
- Float Shares
- 50.24M
Held by 28 ETFs
Biggest fund positions in KARD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | PERCEPTIVE ADVISORS LLC | other | 20,706 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KARD coverage
Recent articles, reports, and earnings notes.
Want a deeper read on KARD?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
businesswire.com · Jun 22
Kardigan rises in Nasdaq debut after upsized $400 million IPO
reuters.com · Jun 18
Kardigan Announces Pricing of Upsized Initial Public Offering
businesswire.com · Jun 17
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
reuters.com · Jun 11
Kardigan Begins Process For IPO On Cardiovascular Treatments Promise
seekingalpha.com · Jun 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Bullish or bearish?
Where do you stand on KARD?